Simeone says that the biggest challenge in pancreatic cancer is the extreme skepticism in the community. There are many new therapies that are available, as well as exciting new clinical trials, but only about 4% of patients with pancreatic cancer go on clinical trials, says Simeone. Watch and listen to more . . .
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.